Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future...

Area of Science:

• Ophthalmology
• Vascular Biology
• Pharmacology

Background:

• Vascular endothelial growth factor (VEGF) is crucial in neovascularization and edema in chorioretinal vascular diseases.
• Current intravitreal therapies (e.g., aflibercept, ranibizumab) improve visual acuity and macular health but necessitate frequent administration.
• Physician-guided treatment adjustments (PRN, treat-and-extend) still require regular clinic visits.

Purpose of the Study:

• To review the current landscape of anti-VEGF therapies for chorioretinal vascular conditions.
• To discuss the challenges and limitations in developing longer-acting treatments.
• To assess the future outlook for treatment frequency and standard of care.

Main Methods:

• Review of clinical trial data and real-world practice patterns for anti-VEGF therapies.
• Analysis of pharmacokinetic profiles and clinical outcomes of existing and investigational long-acting agents.
• Evaluation of the success and failures of novel drug delivery systems and long-acting formulations.

Main Results:

• Intravitreal anti-VEGF drugs demonstrate efficacy in improving visual acuity and macular morphology.
• Phase III trials often show less frequent injection needs than real-world clinical practice.
• Investigational long-acting therapies, including soluble VEGF receptors, have not met success in early trials.

Conclusions:

• Despite advances, frequent intravitreal injections remain the standard of care for managing chorioretinal vascular conditions.
• Developing effective long-acting therapies with sustained clinical benefit is challenging.
• Future research is needed to overcome limitations and potentially reduce treatment burden.